Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $39.6600 (-4.96%) ($39.4800 - $41.7300) on Mon. Jan. 29, 2018. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.42% (three month average) | RSI | 78 | Latest Price | $39.6600(-4.96%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.6% a day on average for past five trading days. | Weekly Trend | ADMS advances 9.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(26%) IBB(24%) IWM(19%) IWO(19%) QQQ(19%) | Factors Impacting ADMS price | ADMS will decline at least -2.21% in a week (0% probabilities). VIXM(-13%) UNG(-9%) BNDX(-9%) UUP(-8%) TLT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.21% (StdDev 4.42%) | Hourly BBV | 0 () | Intraday Trend | -4.9% | | | |
|
5 Day Moving Average | $41.12(-3.55%) | 10 Day Moving Average | $39.54(0.3%) | 20 Day Moving Average | $37.06(7.02%) | To recent high | -7% | To recent low | 68% | Market Cap | $1.122b | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |